{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'treatment as recommended by their treating physician and according to the accepted standard of', 'care.', '8.3.2.', 'Subject Discontinuation from Study Drug', 'A subject will be permanently discontinued from study drug for any of the following reasons,', 'which will be recorded in the source documents and CRF.', 'Emergence of any laboratory abnormality or AE that in the judgment of the', 'Investigator compromises the ability of the subject to continue study-specific', \"procedures or it is considered not to be in the subject's best interest due to an altered\", 'risk/benefit profile.', 'Recurrence of treatment-emergent AST or ALT elevation > 5 X ULN (confirmed) if', 'BCX7353 is restarted after meeting hold criteria as outlined in Section 12.2.2.', 'Treatment-emergent ALT or AST > 3 X ULN combined with either laboratory', \"abnormalities indicative of significant hepatic toxicity (ie, meeting Hy's law, total\", 'bilirubin > 2 X ULN OR with an international normalized ratio [INR] > 1.5 or with', 'symptomatology of acute hepatitis [ie, severe fatigue, nausea, vomiting, right upper', 'quadrant pain and tenderness, fever, rash, and/or eosinophilia (> 5%)]).', 'Subsequent determination that inclusion/exclusion criteria were not met', 'Intercurrent illness or emergence of a new illness/medical condition that would, in the', 'judgment of the Investigator, affect assessments of clinical status to a significant', 'degree.', 'Subject noncompliance with study drug or to the protocol.', 'The subject has a QTcF > 500 msec (confirmed on repeat ECG testing).', 'The subject has a QTcF increase of more than 60 msec (confirmed by repeat ECG)', 'from the mean QTcF value obtained from triplicate ECGs obtained at the Baseline', 'visit and a simultaneous absolute QTcF > 450 msec (males) or > 470 msec (females).', 'Subjects with a study drug related Grade 3 or 4 rash as described by the Division of', 'Microbiology and Infectious Diseases (DMID) criteria \"Skin-mucocutaneous\" will be', 'discontinued from study drug and treated according to best medical practice. All', 'subjects with a suspected drug rash should undergo specific rash evaluation as', 'described in Section 12.2.1. A Grade 3 rash is defined as vesiculation or moist', 'desquamation or ulceration and a Grade 4 rash is defined as exfoliative dermatitis,', 'mucous membrane involvement or erythema multiforme or suspected', 'Stevens-Johnson syndrome or necrosis requiring surgery. Subjects with a Grade 1 or', '2 study-drug related rash may be continued on BCX7353 if the Investigator, subject', 'and Sponsor deem it appropriate. The protocol for continuing BCX7353 in the', 'presence of a rash is described in Section 12.2.1.', 'Subjects who discontinue from study drug in Parts 1 or 2 will be requested to complete all', 'regularly scheduled visits and procedures outlined in Table 2 or Table 3, respectively, through', 'the end of the study part (ie, Part 1 or 2) in which they were being treated. Subjects who', 'discontinue in Part 1 will be requested to complete all regularly scheduled visits and procedures', '45']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'through Week 24. Subjects who discontinue in Part 2 will be requested to complete all regularly', 'scheduled visits and procedures through Week 48. Subjects who discontinue in Part 3 will have', 'an Early Termination visit 3 weeks after their last dose of study drug. All subjects who', 'discontinue from all parts should be treated in accordance with local clinical practice for HAE.', 'If a subject who discontinues from study drug subsequently withdraws consent to continue study', 'visits as previously outlined, please see Section 8.3.1.', 'Subjects are not eligible for treatment in Parts 2 or 3 if they discontinue study drug in Parts 1 or', '2, respectively, due to any of the above cited reasons.', '8.4.', 'End of Study Definition', 'The end of study will be defined as when the last subject completes the last protocol-scheduled', 'visit.', '9.', 'TREATMENT OF SUBJECTS', '9.1.', 'Description of Study Drug and Study Drug Product', 'BCX7353 is an oral small molecule inhibitor of plasma kallikrein. All subjects will receive', 'BCX7353 (150 or 110 mg) or matching placebo (Part 1 only) capsules for oral administration', 'once daily for 24 to up to 144 weeks. Study drug in this study consists of BCX7353 and placebo', 'capsules.', 'The investigational active pharmaceutical ingredient (API) is BCX7353, which is supplied as', '55 or 75 mg capsules in Parts 1 and 2 and 110 or 150 mg capsules in Part 3. The capsules are', 'comprised of the API (BCX7353) blended with the excipients pregelatinized starch,', 'polyplasdone XL, colloidal silicon dioxide, and magnesium stearate in a gelatin capsule.', 'The matching placebo will also be provided as capsules to match the BCX7353. The matching', 'placebo will contain microcrystalline cellulose.', 'In Parts 1 and 2, subjects will be instructed to take 2 capsules of study drug together daily. In', 'Part 3, subjects will take a single capsule of study drug daily.', 'Additional details for the chemical and physical characteristics of BCX7353 may be found in', 'the IB.', '9.2.', 'Description of Study Drug Packaging, Labeling, and Storage', 'The study drug will be packaged in bottles. Subjects will be dispensed a sufficient number of', 'bottles and capsules to cover the dosing period until the next study visit.', 'Each container of study drug will be labeled with the information required per local law and may', 'include: Sponsor name, study protocol number, description of the contents, a statement regarding', 'the investigational (clinical trial) use of the study drug, expiry date, and kit number.', 'Study drug must be stored between 15\u00b0C and 25\u00b0C (room temperature).', 'Details on the study drug packaging, labeling, shipment, storage and dispensing will be provided', 'in the investigational medicinal product (IMP) manual.', '46']\n\n###\n\n", "completion": "END"}